Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015’, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Bile Duct Cancer (Cholangiocarcinoma) Overview
- Therapeutics Development
- Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview
- Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis
- Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies
- Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies
- Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes
- Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development
- 4SC AG
- Agios Pharmaceuticals, Inc.
- Ariad Pharmaceuticals, Inc.
- ArQule, Inc.
- Array BioPharma Inc.
- Arrien Pharmaceuticals, LLC
- AstraZeneca PLC
- Bayer AG
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- CellAct Pharma GmbH
- Concordia Healthcare Corp.
- Cornerstone Pharmaceuticals, Inc.
- Delcath Systems, Inc.
- Eli Lilly and Company
- Exelixis, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Komipharm International Co., Ltd.
- Mebiopharm Co., Ltd.
- Merck & Co., Inc.
- Merrimack Pharmaceuticals, Inc.
- Novartis AG
- NuCana BioMed Limited
- OncoTherapy Science, Inc.
- Panacea Pharmaceuticals, Inc.
- PCI Biotech AS
- Pfizer Inc.
- Provecs Medical GmbH
- Sanofi
- Senhwa Biosciences, Inc.
- Spectrum Pharmaceuticals, Inc.
- Threshold Pharmaceuticals, Inc.
- VasGene Therapeutics, Inc.
- Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
- AG-120 - Drug Profile
- ARN-5032 - Drug Profile
- ARQ-087 - Drug Profile
- BBI-503 - Drug Profile
- BGJ-398 - Drug Profile
- binimetinib - Drug Profile
- cabozantinib s-malate - Drug Profile
- CAP-7.1 - Drug Profile
- CC-90007 - Drug Profile
- CPI-613 - Drug Profile
- dasatinib - Drug Profile
- DKN-01 - Drug Profile
- elpamotide - Drug Profile
- evofosfamide - Drug Profile
- gemcitabine hydrochloride - Drug Profile
- Im-01 - Drug Profile
- KML-001 - Drug Profile
- MBPY-005 - Drug Profile
- melphalan - Drug Profile
- merestinib - Drug Profile
- MK-2206 - Drug Profile
- NUC-1031 - Drug Profile
- OCVC-01 - Drug Profile
- paclitaxel albumin bound - Drug Profile
- PAN-622 - Drug Profile
- pembrolizumab - Drug Profile
- ponatinib hydrochloride - Drug Profile
- porfimer sodium - Drug Profile
- Recombinant Protein to Antagonize EphB4 Receptor for Oncology - Drug Profile
- refametinib - Drug Profile
- regorafenib - Drug Profile
- resminostat - Drug Profile
- RRX-001 - Drug Profile
- SAR-408701 - Drug Profile
- selumetinib sulfate - Drug Profile
- seribantumab - Drug Profile
- silmitasertib - Drug Profile
- SPI-1620 - Drug Profile
- sunitinib malate - Drug Profile
- trametinib dimethyl sulfoxide - Drug Profile
- Vaccine for Metastatic Cholangiocarcinoma - Drug Profile
- vemurafenib - Drug Profile
- Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates
- Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects
- Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products
- Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015
- Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Development by Companies, H1 2015 (Contd..1)
- Number of Products under Development by Companies, H1 2015 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H1 2015
- Comparative Analysis by Late Stage Development, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Development, H1 2015
- Products under Development by Companies, H1 2015
- Products under Development by Companies, H1 2015 (Contd..1)
- Products under Development by Companies, H1 2015 (Contd..2)
- Products under Investigation by Universities/Institutes, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca PLC, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia Healthcare Corp., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by GlaxoSmithKline Plc, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co., Ltd., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co., Ltd., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co., Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech AS, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics, Inc., H1 2015
- Assessment by Monotherapy Products, H1 2015
- Assessment by Combination Products, H1 2015
- Number of Products by Stage and Target, H1 2015
- Number of Products by Stage and Mechanism of Action, H1 2015
- Number of Products by Stage and Route of Administration, H1 2015
- Number of Products by Stage and Molecule Type, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H1 2015
- Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2015
- List of Figures
- Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015
- Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Number of Products by Top 10 Targets, H1 2015
- Number of Products by Stage and Top 10 Targets, H1 2015
- Number of Products by Top 10 Mechanism of Actions, H1 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
- Number of Products by Top 10 Routes of Administration, H1 2015
- Number of Products by Stage and Top 10 Routes of Administration, H1 2015
- Number of Products by Top 10 Molecule Types, H1 2015
- Number of Products by Stage and Top 10 Molecule Types, H1 2015